Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-10
2011-11-29
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
08067385
ABSTRACT:
Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for the prophylaxis treatment of cancer caused by oncoviruses in a human or animal. The methods typically involve administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of at least oligonucleotide that does not act by a sequence complementary mode of action.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4426330 (1984-01-01), Sears
patent: 4469863 (1984-09-01), Ts′o et al.
patent: 4534899 (1985-08-01), Sears
patent: 4615697 (1986-10-01), Robinson
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5023252 (1991-06-01), Hseih
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5218103 (1993-06-01), Caruthers et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5248670 (1993-09-01), Draper et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5278302 (1994-01-01), Caruthers et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5452496 (1995-09-01), Long et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5556948 (1996-09-01), Tagwa et al.
patent: 5563050 (1996-10-01), Peyman et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5591720 (1997-01-01), Anderson et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5602244 (1997-02-01), Caruthers et al.
patent: 5610289 (1997-03-01), Cook et al.
patent: 5625050 (1997-04-01), Beaton et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5670634 (1997-09-01), Marotta et al.
patent: 5684148 (1997-11-01), Caruthers et al.
patent: 5695979 (1997-12-01), Caruthers et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 5837449 (1998-11-01), Monia et al.
patent: 5952490 (1999-09-01), Hanecak et al.
patent: 5998602 (1999-12-01), Torrence et al.
patent: 6013240 (2000-01-01), Behr et al.
patent: 6013639 (2000-01-01), Peyman et al.
patent: 6133246 (2000-10-01), McKay et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6177246 (2001-01-01), Monia et al.
patent: 6184369 (2001-02-01), Rando et al.
patent: 6316190 (2001-11-01), Rein et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6506559 (2003-01-01), Driver et al.
patent: 6573099 (2003-06-01), Graham
patent: 6608035 (2003-08-01), Agrawal et al.
patent: 7358068 (2008-04-01), Vaillant et al.
patent: 2003/0119019 (2003-06-01), Winnacker et al.
patent: 2003/0162225 (2003-08-01), James et al.
patent: 2003/0232435 (2003-12-01), Dobie
patent: 2005/0009743 (2005-01-01), Sundquist et al.
patent: 0 339 842 (1989-11-01), None
patent: 0 445 131 (1991-09-01), None
patent: 0 445 131 (1991-09-01), None
patent: 0 496 813 (1992-08-01), None
patent: 0 496 813 (1992-08-01), None
patent: 90/04384 (1990-05-01), None
patent: WO 90/04384 (1990-05-01), None
patent: 91/05545 (1991-05-01), None
patent: WO 91/05545 (1991-05-01), None
patent: WO 92/03051 (1992-03-01), None
patent: 93/24510 (1993-12-01), None
patent: 94/02499 (1994-02-01), None
patent: WO 94/02499 (1994-02-01), None
patent: 94/17093 (1994-08-01), None
patent: WO 94/17093 (1994-08-01), None
patent: 94/20073 (1994-09-01), None
patent: WO 94/20073 (1994-09-01), None
patent: 94/26794 (1994-11-01), None
patent: WO 94/26764 (1994-11-01), None
patent: 96/10391 (1996-04-01), None
patent: WO 96/10391 (1996-04-01), None
patent: 96/40062 (1996-12-01), None
patent: WO 96/40062 (1996-12-01), None
patent: 97/04787 (1997-02-01), None
patent: WO 97/04787 (1997-02-01), None
patent: 97/13499 (1997-04-01), None
patent: WO 97/13499 (1997-04-01), None
patent: 97/30731 (1997-08-01), None
patent: WO 97/30731 (1997-08-01), None
patent: 98/39352 (1998-09-01), None
patent: WO 98/39352 (1998-09-01), None
patent: 99/14226 (1999-03-01), None
patent: WO 99/14226 (1999-03-01), None
patent: 99/32619 (1999-07-01), None
patent: WO 99/32619 (1999-07-01), None
patent: 01/75164 (2001-10-01), None
patent: WO 01/75164 (2001-10-01), None
patent: 92/03051 (2002-03-01), None
patent: 02/068582 (2002-09-01), None
patent: WO 02/068582 (2002-09-01), None
patent: WO 03/097661 (2002-11-01), None
patent: WO 03/002903 (2003-01-01), None
patent: 03/097661 (2003-11-01), None
patent: 2004/002419 (2004-01-01), None
patent: WO 2004/002419 (2004-01-01), None
Crooke, S., Ann. Rev. Medicine, vol. 55, pp. 61-95 (2004).
Peracchi et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Chirila et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Opalinska et al., Nature Rev., vol. 1, pp. 503-514 (2002).
Trus et al., J. Molec. Biol., vol. 263, pp. 447-462 (1996).
Adjou et al., “A novel generation of heparan sulfate mimetics for the treatment of prion diseases”, 2003,J. Gen. Virol.84:2595-2603.
Agrawal, “Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides”, 1999,Biochim. Biophys. Acta1489:53-68.
Agrawal and Kandimalla, “Antisense therapeutics: is it as simple as complementary base recognition?”, 2000,Mol. Med. Today6:72-81.
Akhtar et al., “The delivery of antisense therapeutics”, 2000,Advanced Drug Delivery Reviews44:3-21.
Allakhverdi et al., “Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common β Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma”, 2002,Am. J. Respir. Crit. Care Med.165:1015-1021.
Andreola et al., “DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity”, 2001,Biochemistry, 40:10087-10094.
Baker et al., “2-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells”, 1997,J. Biol. Chem.272 (18):11994-12000.
Ball et al., “Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma”, 2003,Am. J. Pharmacogenomics3 (2):97-106.
Banks et al., “Delivery across the Blood-Brain Barrier of Antisense Directed against Amyloid β: Reversal of Learning and Memory Deficits in Mice Overexpressing Amyloid Precursor Protein”, 2001,J. Pharmacol. Exp. Ther.297 (3):1113-1121.
Bardos et al., “Structure-Activity Relationships and Mode of Action of 5-Mercapto-Substituted Oligo-and Polynucleotides as Antitemplates Inhibiting Replication of Human Immunodeficiency Virus Type 1”, 1992,Antimicrob. Agents and Chemother.36 (1):108-114.
Barret et al., “Evaluation of Quinacrine Treatment for Prion Diseases”, 2003,J. of Virol.77 (15):8462-8469.
Bate et al, “Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity”, 2004,J. of Biol. Chem.279 (15):14983-14990.
Boussif et al., “A versatile Vect
Juteau Jean-Marc
Vaillant Andrew
McGarry Sean
Norton Rose Or LLP
Replicor Inc.
LandOfFree
Antiviral oligonucleotides targeting HBV does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral oligonucleotides targeting HBV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral oligonucleotides targeting HBV will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268495